Trial
NCT02936102
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Advanced Solid Tumors
Intervention
FAZ053
Why stopped
The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-14